This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Health Winners and Losers

Shares of Genomic Health (GHDX) were among the worst-performing health-related stocks Monday, slumping 17% after Piper Jaffray downgraded the stock to market perform from outperform. The firm also cut its price target on the stock to $14.50 from $18.50.

Piper Jaffray cited increased regulatory risk concerning the company's only product, a breast cancer test called Oncotype DX, for the downgrade. Until the regulatory status of the test is cleared up, the firm said, an overhang on the stock could last for some six to 10 months. In late January, the Food and Drug Administration sent a letter to Genomic inviting the company to meet with regulators to discuss the regulatory status of the test and discuss ways in which the company could fulfill any FDA premarket review requirements that might apply. Shares recently were trading down $2.53 to $12.07.

Oscient Pharmaceuticals (OSCI) fell 8% Monday, even though the drugmaker posted better-than-expected fourth-quarter results. The company reported a loss of $17.1 million, or 22 cents a share, on revenue of $9.5 million. Analysts polled by Thomson First Call expected a loss of 29 cents a share and revenue of $9.1 million. A year earlier, the company recorded a loss of $32.3 million, or 43 cents a share, on revenue of $2.7 million. The company said its most recent results were fueled by strong sales of Factive tablets and Testim testosterone gel. Shares recently traded at $2, down 18 cents.

Shares of Medicines Co. (MDCO) fell 2% after the drug developer announced the resignation of its chief financial officer. The company said Steve Koehler, who had served as CFO for four years, will step down on March 17 to take a position with a pharmaceutical company. Koehler will be replaced by Glenn Sblendorio, who most recently served as chief financial officer at Eyetech Pharmaceuticals, which was acquired in November by OSI Pharmaceuticals (OSIP). Medicines Co. shares were trading down 49 cents to $19.62.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs